Articles related to CLINICAL TRIALS

In a recent phase 2 trial, frexalimab, targeting the CD40-CD40L pathway, demonstrated a notable reduction in new gadolinium-enhancing T1-weighted lesions in patients with relapsing multiple sclerosis.

In the KEYNOTE-564 trial, adjuvant pembrolizumab demonstrated a significant improvement in disease-free survival among patients with renal-cell carcinoma at high risk of recurrence after nephrectomy, offering a new direction in post-surgical treatment strategies.

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.

In the fast-evolving landscape of oncology treatment, a new study reveals oncologists’ unique stance on FDA approval processes, emphasizing the importance of timely access to potentially life-saving drugs despite conventional evidentiary standards.

This study underscores the critical need for precise diagnostic criteria in treating unexplained strokes and the potential reevaluation of anticoagulant use in patients with atrial cardiopathy, opening new avenues for research and patient care.